title: The efficacy and safety of argon plasma coagulation therapy in Barrett's esophagus.
abstract: BACKGROUND
  Thermoablation is being used to eliminate the metaplastic epithelium of Barrett's esophagus and allow its reversal into squamous epithelium in an acid-controlled environment. This study assessed the efficacy and safety of a new thermoablation technique, argon plasma coagulation.
  
  
  METHODS
  Patients with circumferential Barrett's esophagus 2 to 5 cm long were enrolled. Acid suppression was accomplished with lansoprazole. One-half the circumference of Barrett's mucosa was treated with argon plasma coagulation, and the other half served as an internal control. After macroscopic squamous re-epithelialization occurred, biopsy specimens were obtained from both areas systematically.
  
  
  RESULTS
  Nine patients, all men with a mean age of 51.1 years, completed the study. During 24-hour esophageal pH monitoring a pH less than 4 occurred on average 2.8% of the time with a mean dose of lansoprazole of 70 mg/day. Squamous re-epithelialization developed in treated areas in all 9 patients. Biopsy showed that 7 of 9 patients (77.8%) had squamous re-epithelialization without intestinal metaplasia. Biopsy showed that 2 of 9 patients (22.2%) had squamous re-epithelialization with evidence of underlying intestinal metaplasia. There were no serious complications.
  
  
  CONCLUSIONS
  Argon plasma coagulation in an acid-controlled environment was both efficacious and safe in the treatment of Barrett's esophagus. However, the reappearance of squamous epithelium after therapy did not exclude the presence of underlying intestinal metaplasia.
authors.affiliation: Department of Medicine, Gastroenterology Section, Carl T. Hayden VA Medical Center, Phoenix, Arizona 85012, USA.
authors.forename: A J
authors.initials: AJ
authors.lastname: Grade
authors.forename: I A
authors.initials: IA
authors.lastname: Shah
authors.forename: S M
authors.initials: SM
authors.lastname: Medlin
authors.forename: F C
authors.initials: FC
authors.lastname: Ramirez
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001471:Barrett Esophagus / Q000473:pathology / Q000601:surgery*; D001706:Biopsy; D019723:Endoscopes; D004724:Endoscopy / Q000009:adverse effects / Q000379:methods* / Q000706:statistics & numerical data; D004945:Esophagoscopy; D004947:Esophagus / Q000473:pathology / Q000601:surgery; D006801:Humans; D064747:Lansoprazole; D008028:Light Coagulation / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods* / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D011300:Preoperative Care; D012449:Safety
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D009853:Omeprazole